Quizartinib Dihydrochloride

CHEMBL2105709 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
633.6 g/mol
LogP
Phase
4

Quizartinib dihydrochloride is the dihydrochloride salt form of quizartinib, a selective FLT3 kinase inhibitor approved for the treatment of FLT3-ITD positive acute myeloid leukemia. See quizartinib for complete pharmacological details.

Berat Molekul

633,6000 g/mol

TPSA

134,00 Ų

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1.Cl.Cl

InChI

InChI=1S/C29H32N6O4S.2ClH/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34;;/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36);2*1H

Molecular Formula

C29H34Cl2N6O4S

HBD / HBA

4 / 8

Ikatan yang Dapat Dirotasi

8

Atom Berat

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Quizartinib dihydrochloride is the dihydrochloride salt form of quizartinib, a selective FLT3 kinase inhibitor approved for the treatment of FLT3-ITD positive acute myeloid leukemia. See quizartinib for complete pharmacological details.

Yes, Quizartinib Dihydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105709. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25184035. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.